Birgit Girshick Sells 6,500 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the transaction, the chief executive officer owned 36,013 shares in the company, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock traded down $2.59 during trading hours on Thursday, hitting $281.78. 1,054,824 shares of the stock were exchanged, compared to its average volume of 929,021. The stock has a market capitalization of $13.45 billion, a P/E ratio of -58.10, a P/E/G ratio of 2.92 and a beta of 1.38. The business’s 50-day moving average is $220.98 and its two-hundred day moving average is $190.27. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $288.02.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities research analysts expect that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of research reports. Barclays restated an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. TD Cowen raised their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research report on Monday. Finally, CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a research report on Monday, July 20th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $255.65.

Hedge Funds Weigh In On Charles River Laboratories International

Several large investors have recently made changes to their positions in CRL. Invesco Ltd. lifted its holdings in Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after buying an additional 1,446,972 shares during the period. Victory Capital Management Inc. grew its holdings in Charles River Laboratories International by 9,938.8% during the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares during the period. Ameriprise Financial Inc. grew its holdings in Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after acquiring an additional 575,039 shares during the period. Amundi raised its position in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at $96,765,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.